Safety and Efficacy of Medical Cannabis in Fibromyalgia Iftach Sagy, Lihi Bar-Lev Schleider, Mahmoud Abu-Shakra and Victor Novack Journal of Clinical Medicine, 2019, 8, 807 doi : 10.3390/jcm8060807 Abstract : Background : Chronic pain may be treated by medical cannabis. Yet, there is scarce evidence to support the role of medical cannabis in the treatment of fibromyalgia. The aim of the study was to investigate the characteristics, safety, and eectiveness of medical cannabis therapy for fibromyalgia. Methods : A prospective observational study with six months follow-up period based on fibromyalgia patients who were willing to answer questionnaire in a specialized medical cannabis clinic between 2015 and 2017. Results : Among the [...]
Lire la suiteFDA, FTC warn company marketing unapproved cannabidiol products with unsubstantiated claims to treat teething and ear pain in infants, autism, ADHD, Parkinson’s and Alzheimer’s disease FDA is also working quickly to evaluate regulatory policies related to cannabis and cannabis-derived ingredients like CBD October 22, 2019 https://www.fda.gov/news-events/press-announcements/fda-ftc-warn-company-marketing-unapproved-cannabidiol-products-unsubstantiated-claims-treat-teething Today, the U.S. Food and Drug Administration and the Federal Trade Commission posted a joint warning letter to Rooted Apothecary LLC, of Naples, Florida, for illegally selling unapproved products containing cannabidiol (CBD) online with unsubstantiated claims that the products treat teething pain and ear aches in infants, autism, attention-deficit/hyperactivity disorder (ADHD), as well as Parkinson’s and Alzheimer’s disease, [...]
Lire la suiteCould cannabidiol be used as an alternative to antipsychotics ? Marc Fakhoury Journal of Psychiatric Research · May 2016 Doi : 10.1016/j.jpsychires.2016.05.013 Abstract Schizophrenia is a mental disorder that affects close to 1% of the population. Individuals with this disorder often present signs such as hallucination, anxiety, reduced attention, and social withdrawal. Although antipsychotic drugs remain the cornerstone of schizophrenia treatment, they are associated with severe side effects. Recently, the endocannabinoid system (ECS) has emerged as a potential therapeutic target for pharmacotherapy that is involved in a wide range of disorders, including schizophrenia. Since its discovery, a lot of effort has been devoted to the [...]
Lire la suiteCannabinoids for the treatment of mental disorders and symptoms of mental disorders : a systematic review and meta-analysis Nicola Black, Emily Stockings, Gabrielle Campbell, Lucy T. Tran, Dino Zagic, Wayne D. Hall, Michael Farrell, Louisa Degenhardt Lancet Psychiatry, 2019 https://doi.org/10.1016/S2215-0366(19)30401-8 Summary Background : Medicinal cannabinoids, including medicinal cannabis and pharmaceutical cannabinoids and their synthetic derivatives, such as tetrahydrocannabinol (THC) and cannabidiol (CBD), have been suggested to have a therapeutic role in certain mental disorders. We analysed the available evidence to ascertain the effectiveness and safety of all types of medicinal cannabinoids in treating symptoms of various mental disorders. Methods : For this systematic review and meta-analysis [...]
Lire la suiteCannabidiol as a potential treatment for psychosis Cathy Davies and Sagnik Bhattacharyya Therapeutic Advances in Psychopharmacology, 2019, Vol. 9, 1–16 https://doi.org/10.1177%2F2045125319881916 Abstract : Psychotic disorders such as schizophrenia are heterogeneous and often debilitating conditions that contribute substantially to the global burden of disease. The introduction of dopamine D2 receptor antagonists in the 1950s revolutionised the treatment of psychotic disorders and they remain the mainstay of our treatment arsenal for psychosis. However, traditional antipsychotics are associated with a number of side effects and a significant proportion of patients do not achieve an adequate remission of symptoms. There is therefore a need for novel interventions, particularly those with a non-D2 antagonist mechanism of [...]
Lire la suiteCannabidiol as a potential treatment for psychosis C.D. Schubart, I.E.C. Sommer, P. Fusar-Poli, L. de Witte, R.S. Kahn, M.P.M. Boks European Neuropsychopharmacology, 2014, 24 ,(1), 51–64. http://dx.doi.org/10.1016/j.euroneuro.2013.11.002 Abstract Although cannabis use is associated with an increased risk of developing psychosis, the cannabis constituent cannabidiol (CBD) may have antipsychotic properties. This review concisely describes the role of the endocannabinoid system in the development of psychosis and provides an overview of currently available animal, human experimental, imaging, epidemiological and clinical studies that investigated the antipsychotic properties of CBD. In this targeted literature review we performed a search for English articles using Medline and EMBASE. Studies were selected if [...]
Lire la suiteCannabinoids and Mental Health, Part 1 : The Endocannabinoid System and Exogenous Cannabinoids Andrew Penn Journal of Psychosocial Nursing and Mental Health Services, 2019, 57, 9, 7-10. Doi : 10.3928/02793695-20190813-01 ABSTRACT The increasing public acceptance of cannabis and the proliferation of cannabis products in the market-place has coincided with more patients using the drug as a substitute for psychiatric medications or as an adjunctive treatment modality for psychiatric conditions, despite limited evidence of efficacy. With a goal of furthering harm-reduction eff orts in psychiatric nursing, the current article reviews the fundamentals of the endocannabinoid system in humans and the exogenous phytocannabinoids that act on this regulatory [...]
Lire la suiteTherapeutic potential of cannabinoids in schizophrenia, KUCEROVA J., TABIOVA K., DRAGO F., MICALE V. Recent Patents on CNS Drug Discovery, 2014, 9, (1), 13-25. Doi : 10.2174/1574889809666140307115532 Abstract Increasing evidence suggests a close relationship between the endocannabinoid system and schizophrenia. The endocannabinoid system comprises of two G protein-coupled receptors (the cannabinoid receptors 1 and 2 [CB1 and CB2] for marijuana's psychoactive principle Δ(9)-tetrahydro-cannabinol), their endogenous small lipid ligands (namely anandamide [AEA] and 2-arachidonoyl-glycerol [2-AG], also known as endocannabinoids), and proteins for endocannabinoid biosynthesis and degradation. It has been suggested to be a pro-homeostatic and pleiotropic signalling system activated in a time- and tissue-specific manner during [...]
Lire la suiteMedical use of cannabis. Cannabidiol: a new light for schizophrenia ? Serena Deiana Drug Testing and Analysis, 2013, 5, (1), 46-51 doi: 10.1002/dta.1425. Abstract The medical properties of cannabis have been known for many centuries; its first documented use dates back to 2800 BC when it was described for its hallucinogenic and pain-relieving properties. In the first half of the twentieth century, a number of pharmaceutical companies marked cannabis for indications such as asthma and pain, but since then its use has sharply declined, mainly due to its unpredictable effects, but also for socio-political issues. Recently, great attention has been directed to the medical properties [...]
Lire la suiteCannabinoids and Schizophrenia : Risks and Therapeutic Potential Marc W. Manseau & Donald C. Goff Neurotherapeutics, 2015, 12, 816–824 DOI 10.1007/s13311-015-0382-6 # The American Society for Experimental NeuroTherapeutics, Inc. 2015 Abstract A convergence of evidence shows that use of Cannabis sativa is associated with increased risk of developing psychotic disorders, including schizophrenia, and earlier age at which psychotic symptoms first manifest. Cannabis exposure during adolescence is most strongly associated with the onset of psychosis amongst those who are particularly vulnerable, such as those who have been exposed to child abuse and those with family histories of schizophrenia. Schizophrenia that develops after cannabis use may have a [...]
Lire la suite